Cargando…
Treatment with Volanesorsen, a 2′-O-Methoxyethyl-Modified Antisense Oligonucleotide Targeting APOC3 mRNA, Does Not Affect the QTc Interval in Healthy Volunteers
The aim of this study was to assess the effect of volanesorsen on the corrected QT (QTc) interval. This thorough QT study enrolled 52 healthy male and female subjects who were randomized at a single site in a four-way crossover study. Subjects were randomly assigned to 1 of 12 treatment sequences an...
Autores principales: | Watts, Lynnetta M., Karwatowska-Prokopczuk, Ewa, Hurh, Eunju, Alexander, Veronica J., Balogh, Kristin, O'Dea, Louis, Geary, Richard S., Tsimikas, Sotirios |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mary Ann Liebert, Inc., publishers
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7415887/ https://www.ncbi.nlm.nih.gov/pubmed/32589506 http://dx.doi.org/10.1089/nat.2019.0837 |
Ejemplares similares
-
N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels
por: Alexander, Veronica J, et al.
Publicado: (2019) -
Integrated Assessment of the Clinical Performance of GalNAc(3)-Conjugated 2′-O-Methoxyethyl Chimeric Antisense Oligonucleotides: I. Human Volunteer Experience
por: Crooke, Stanley T., et al.
Publicado: (2019) -
Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia
por: Gaudet, Daniel, et al.
Publicado: (2020) -
Integrated Assessment of Phase 2 Data on GalNAc(3)-Conjugated 2′-O-Methoxyethyl-Modified Antisense Oligonucleotides
por: Baker, Brenda F., et al.
Publicado: (2023) -
Case report: desensitization of hypersensitivity against the antisense oligonucleotide volanesorsen
por: Isaac, Rafael H., et al.
Publicado: (2023)